Arrow Meds

Arrowhead Pharmaceuticals is a clinical-stage biopharmaceutical company specializing in the development of RNA interference (RNAi) therapeutics to treat intractable diseases by silencing the genes that cause them. The company utilizes its proprietary Targeted RNAi Molecule (TRiM) platform to design therapies that offer high potency and specificity while maintaining a favorable safety profile. Arrowhead's diverse pipeline includes advanced programs targeting liver-based diseases, such as hepatitis B and alpha-1 antitrypsin deficiency, as well as expanding efforts into extra-hepatic tissues like the lung and muscle. Through strategic partnerships with major pharmaceutical firms, the company is positioning itself as a leader in the rapidly evolving field of genetic medicine.